Clinical Trials
7
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2013
Completed
3
42.9%
Recruiting
4
57.1%
No approval data available
- Teva Pharmaceuticals received FDA Fast Track designation for emrusolmin (TEV-56286), an investigational small molecule therapy targeting alpha-synuclein protein for Multiple System Atrophy treatment. - The therapy is currently in Phase 2 development through a strategic collaboration with German biotech company MODAG GmbH and previously received FDA Orphan Drug designation in 2022. - Multiple System Atrophy affects approximately 40,000 people in the US, EU, and Japan with no current treatments available that impact disease progression. - Fast Track designation facilitates expedited development and review for drugs addressing serious conditions with urgent unmet medical needs.
- The global Multiple System Atrophy (MSA) market is experiencing significant growth driven by emerging alpha-synuclein targeting therapies and advanced diagnostic technologies including high-resolution MRI and biomarker identification. - Over 20 companies are developing 22+ MSA treatment therapies across various clinical phases, with recent FDA Fast Track designations granted to ATH434 by Alterity Therapeutics and amlenetug by H. Lundbeck A/S. - Despite promising pipeline developments, the MSA market faces challenges including absence of curative therapies, diagnostic complexity due to symptom overlap with Parkinson's disease, and limited commercial incentives due to the rare patient population. - Leading pharmaceutical companies including Biohaven Pharmaceuticals, Merck & Co., AstraZeneca, and emerging biotech firms are focusing on disease-modifying treatments targeting alpha-synuclein aggregation pathways.
